Systemic sclerosis is a systemic autoimmune disease that can affect the hands leading to a deterioration in function. Unfortunately, current medical treatments are considered insufficient to improve patients’ quality of life. However, innovative surgical and injectable treatments are available.
Patients and methods:
A systematic review of the literature on surgical and injectable treatments available to hand surgeons was carried out according to the PRISMA criteria. All the articles selected were analysed qualitatively and descriptively, and where possible the extracted data were summarised quantitatively.
Results and discussion:
Twenty-nine articles were therefore included, comprising 704 patients and 546 procedures. Nine different treatments were identified. Botulinum toxin injections have shown promising clinical results in the treatment of Raynaud’s phenomenon, digital ulcers and pain, but have not been confirmed in randomised placebo-controlled trials. Injections of adipose-derived stromal vascular fraction showed positive results in Raynaud’s phenomenon, digital ulcer, pain and function, but not in randomised placebo-controlled trials. Autologous fat grafting has shown significant results in Raynaud Phenomenon (RP) and digital ulcers (DUs) healing and prevention. Peripheral sympathectomy has shown moderate beneficial effects with frequent adverse events, and should be reserved for severe cases. Transluminal angioplasty has shown encouraging results, but studies with a high level of evidence are needed. Finally, symptomatic calcinosis cutis should be treated by resection or carbon dioxide (CO2) laser. A treatment algorithm is provided in the Supplemental Appendix.
Conclusion:
Interventional treatments for scleroderma of the hand have shown an overall trend of efficacy, but some of the beneficial effects have not been found in studies with a high level of evidence. Further well-conducted studies are needed.
LeeJJYGignacMAMJohnsonSR. Employment outcomes in systemic sclerosis. Best Pract Res Clin Rheumatol2021; 35(3): 101667.
2.
MalcarneVLFoxRSMillsSD, et al. Psychosocial aspects of systemic sclerosis. Curr Opin Rheumatol2013; 25(6): 707–713.
3.
MeierFMFrommerKWDinserR, et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis2012; 71(8): 1355–1360.
4.
HachullaEClersonPLaunayD, et al. Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J Rheumatol2007; 34(12): 2423–2430.
5.
WirzEGJaegerVKAllanoreY, et al. Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. Ann Rheum Dis2016; 75(7): 1285–1292.
6.
EnnisHVailAWraggE, et al. A prospective study of systemic sclerosis-related digital ulcers: prevalence, location, and functional impact. Scand J Rheumatol2013; 42(6): 483–486.
7.
WigleyFMWiseRASeiboldJR, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med1994; 120(3): 199–206.
8.
WigleyFMSeiboldJRWiseRA, et al. Intravenous iloprost treatment of Raynaud’s phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol1992; 19(9): 1407–1414.
9.
HachullaEHatronPYCarpentierP, et al. Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. Ann Rheum Dis2016; 75(6): 1009–1015.
10.
CutoloMSoldanoSSmithV.Pathophysiology of systemic sclerosis: current understanding and new insights. Expert Rev Clin Immunol2019; 15(7): 753–764.
11.
HarrisonBJSilmanAJHiderSL, et al. Cigarette smoking as a significant risk factor for digital vascular disease in patients with systemic sclerosis. Arthritis Rheum2002; 46(12): 3312–3316.
12.
CaramaschiPBiasiDCaimmiC, et al. Digital amputation in systemic sclerosis: prevalence and clinical associations. A retrospective longitudinal study. J Rheumatol2012; 39(8): 1648–1653.
13.
PooleJL.Musculoskeletal rehabilitation in the person with scleroderma. Curr Opin Rheumatol2010; 22(2): 205–212.
14.
SpiritovicMSmucrovaHHermankovaB, et al. The effect of a 24-week physiotherapy and occupational therapy programme in systemic sclerosis: a monocentric controlled study with follow-up. Clin Exp Rheumatol2022; 40(10): 1941–1950.
15.
DavuluriSLoodCChungL.Calcinosis in systemic sclerosis. Curr Opin Rheumatol2022; 34(6): 319–327.
16.
ValenzuelaABaronMRodriguez-ReynaTS, et al. Calcinosis is associated with ischemic manifestations and increased disability in patients with systemic sclerosis. Semin Arthritis Rheum2020; 50(5): 891–896.
17.
PageMJMcKenzieJEBossuytPM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ2021; 372: n71.
18.
BelloRJCooneyCMMelamedE, et al. The therapeutic efficacy of botulinum toxin in treating scleroderma-associated Raynaud’s phenomenon: a randomized, double-blind, placebo-controlled clinical trial. Arthritis Rheumatol2017; 69(8): 1661–1669.
19.
SenetPMaillardHDiotE, et al. Efficacy and safety of botulinum toxin in adults with Raynaud’s phenomenon secondary to systemic sclerosis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheumatol2023; 75: 459–467.
20.
MotegiSIUeharaAYamadaK, et al. Efficacy of botulinum toxin B injection for Raynaud’s phenomenon and digital ulcers in patients with systemic sclerosis. Acta Derm Venereol2017; 97(7): 843–850.
21.
DuWZhouMZhangC, et al. The efficacy of botulinum toxin A in the treatment of Raynaud’s phenomenon in systemic sclerosis: a randomized self-controlled trial. Dermatol Ther2022; 35(7): e15529.
22.
JokarMHBaghbaniBGeraylowKR, et al. Efficacy of botulinum toxin type A injection for Raynaud’s phenomenon and digital ulcers in patients with systemic sclerosis. Reumatologia2022; 60(6): 392–398.
23.
UppalLDhaliwalKButlerPE.A prospective study of the use of botulinum toxin injections in the treatment of Raynaud’s syndrome associated with scleroderma. J Hand Surg Eur Vol2014; 39(8): 876–880.
24.
ShenavandehSSepaskhahMDehghaniS, et al. A 4-week comparison of capillaroscopy changes, healing effect, and cost-effectiveness of botulinum toxin-A vs prostaglandin analog infusion in refractory digital ulcers in systemic sclerosis. Clin Rheumatol2022; 41(1): 95–104.
25.
DhaliwalKGriffinMFSalinasS, et al. Optimisation of botulinum toxin type a treatment for the management of Raynaud’s phenomenon using a dorsal approach: a prospective case series. Clin Rheumatol2019; 38(12): 3669–3676.
26.
MotegiSYamadaKTokiS, et al. Beneficial effect of botulinum toxin A on Raynaud’s phenomenon in Japanese patients with systemic sclerosis: a prospective, case series study. J Dermatol2016; 43(1): 56–62.
27.
SerriJLegréRVeitV, et al. Botulinum toxin type A contribution in the treatment of Raynaud’s phenomenon due to systemic sclerosis. Ann Chir Plast Esthet2013; 58(6): 658–662.
28.
LautenbachGDobrotaRMihaiC, et al. Evaluation of botulinum toxin A injections for the treatment of refractory chronic digital ulcers in patients with systemic sclerosis. Clin Exp Rheumatol2020; 38(125 Suppl. 3): 154–160.
29.
DaumasAMagalonJJouveE, et al. Adipose tissue-derived stromal vascular fraction for treating hands of patients with systemic sclerosis: a multicentre randomized trial Autologous AD-SVF versus placebo in systemic sclerosis. Rheumatology (Oxford)2022; 61(5): 1936–1947.
30.
KhannaDCaldronPMartinRW, et al. Adipose-derived regenerative cell transplantation for the treatment of hand dysfunction in systemic sclerosis: a randomized clinical trial. Arthritis Rheumatol2022; 74(8): 1399–1408.
31.
ParkYLeeYJKohJH, et al. Clinical efficacy and safety of injection of stromal vascular fraction derived from autologous adipose tissues in systemic sclerosis patients with hand disability: a proof-of-concept trial. J Clin Med2020; 9(9): 3023.
32.
GranelBDaumasAJouveE, et al. Safety, tolerability and potential efficacy of injection of autologous adipose-derived stromal vascular fraction in the fingers of patients with systemic sclerosis: an open-label phase I trial. Ann Rheum Dis2015; 74(12): 2175–2182.
33.
Guillaume-JugnotPDaumasAMagalonJ, et al. Autologous adipose-derived stromal vascular fraction in patients with systemic sclerosis: 12-month follow-up. Rheumatology (Oxford)2016; 55(2): 301–306.
34.
DaumasAMagalonJJouveE, et al. Long-term follow-up after autologous adipose-derived stromal vascular fraction injection into fingers in systemic sclerosis patients. Curr Res Transl Med2017; 65(1): 40–43.
35.
Del PapaNDi LucaGAndraccoR, et al. Regional grafting of autologous adipose tissue is effective in inducing prompt healing of indolent digital ulcers in patients with systemic sclerosis: results of a monocentric randomized controlled study. Arthritis Res Ther2019; 21(1): 7.
36.
Del PapaNDi LucaGSambataroD, et al. Regional implantation of autologous adipose tissue-derived cells induces a prompt healing of long-lasting indolent digital ulcers in patients with systemic sclerosis. Cell Transplant2015; 24(11): 2297–2305.
37.
PignattiMSpinellaACocchiaraE, et al. Autologous fat grafting for the oral and digital complications of systemic sclerosis: results of a prospective study. Aesthetic Plast Surg2020; 44(5): 1820–1832.
38.
StrongALAdidharmaWBrownOH, et al. Fat grafting subjectively improves facial skin elasticity and hand function of scleroderma patients. Plast Reconstr Surg Glob Open2021; 9(1): e3373.
39.
WardWAVan MooreA.Management of finger ulcers in scleroderma. J Hand Surg Am1995; 20(5): 868–872.
40.
RuchDSHoldenMSmithBP, et al. Periarterial sympathectomy in scleroderma patients: intermediate-term follow-up. J Hand Surg Am2002; 27(2): 258–264.
41.
TomainoMMGoitzRJMedsgerTA.Surgery for ischemic pain and Raynaud’s phenomenon in scleroderma: a description of treatment protocol and evaluation of results. Microsurgery2001; 21(3): 75–79.
42.
MomeniASoriceSCValenzuelaA, et al. Surgical treatment of systemic sclerosis–is it justified to offer peripheral sympathectomy earlier in the disease process?Microsurgery2015; 35(6): 441–446.
43.
Romero-KaramLAHonanKAArainSA, et al. Percutaneous revascularization for the treatment of refractory digital ischemia in systemic sclerosis. J Scleroderma Relat Disord2023; 8(1): 36–42.
44.
BottomleyWWGoodfieldMJSheehan-DareRA.Digital calcification in systemic sclerosis: effective treatment with good tissue preservation using the carbon dioxide laser. Br J Dermatol1996; 135(2): 302–304.
45.
KliftoKMChoBHLifchezSD.Surgical debulking for symptomatic management of calcinosis cutis of the hand and upper extremity in systemic sclerosis. J Hand Surg Am2021; 46(10): 928.e1–928.e9.
46.
LapnerMAGoetzTJ.High-speed burr debulking of digital calcinosis cutis in scleroderma patients. J Hand Surg Am2014; 39(3): 503–510.
47.
FahmyFSEvansDMDevarajVS.Microdrilling of digital calcinosis. Eur J Plast Surg1998; 21(7): 378–380.
48.
O’BrienBMKumarPAMellowCG, et al. Radical microarteriolysis in the treatment of vasospastic disorders of the hand, especially scleroderma. J Hand Surg Br1992; 17(4): 447–452.
49.
SoberónJRJr.GreengrassRADavisWE, et al. Intermediate-term follow-up of chronically ill patients with digital ischemia treated with peripheral digital sympathectomy. Rheumatol Int2016; 36(2): 301–307.
50.
HalachmiSGabariOCohenS, et al. Telangiectasis in CREST syndrome and systemic sclerosis: correlation of clinical and pathological features with response to pulsed dye laser treatment. Lasers Med Sci2014; 29(1): 137–140.
51.
HassanienMRashadSMohamedN, et al. Non-invasive Oxygen-Ozone therapy in treating digital ulcers of patients with systemic sclerosis. Acta Reumatol Port2018; 43(3): 210–216.
52.
KaymazSKarasuUAlkanH, et al. Efficacy of local oxygen-ozone therapy for the treatment of digital ulcer refractory to medical therapy in systemic sclerosis: a randomized controlled study. Mod Rheumatol2022; 32(6): 1102–1107.
53.
BeneMDPozziMRRovatiL, et al. Autologous fat grafting for scleroderma-induced digital ulcers. An effective technique in patients with systemic sclerosis. Handchir Mikrochir Plast Chir2014; 46(4): 242–247.
54.
van Rhijn-BrouwerFCCGremmelsHFledderusJO, et al. A randomised placebo-controlled double-blind trial to assess the safety of intramuscular administration of allogeneic mesenchymal stromal cells for digital ulcers in systemic sclerosis: the MANUS Trial protocol. BMJ Open2018; 8(8): e020479.
55.
Kowal-BieleckaOFransenJAvouacJ, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis2017; 76(8): 1327–1339.
56.
PopeJEDentonCPJohnsonSR, et al. State-of-the-art evidence in the treatment of systemic sclerosis. Nat Rev Rheumatol2023; 19(4): 212–226.
57.
BeldnerSRabinovichRVPolatschDB.Scleroderma of the hand: evaluation and treatment. J Am Acad Orthop Surg2020; 28(16): e686–695.
ZukPAZhuMMizunoH, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng2001; 7(2): 211–228.
62.
BourinPBunnellBACasteillaL, et al. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). Cytotherapy2013; 15(6): 641–648.
63.
ChaputBBertheuilNEscubesM, et al. Mechanically isolated stromal vascular fraction provides a valid and useful collagenase-free alternative technique: a comparative study. Plast Reconstr Surg2016; 138(4): 807–819.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
